Meta-analysis of randomized controlled trials of bosentan for treatment of pulmonary arterial hypertension

Korean Journal of Internal Medicine

Volumn 28, Issue 6, 2013, Pages 701-707

  Lee, Young Ho ^a   Song, Gwan Gyu ^a  

^a Korea University College of Medicine   (South Korea)

Author keywords

Bosentan; Efficacy; Hypertension; Pulmonary; Safety

Indexed keywords

BOSENTAN; PLACEBO; PROSTACYCLIN;

ADVERSE DRUG REACTION; ARTICLE; COCHRANE LIBRARY; DRUG EFFICACY; DRUG SAFETY; EMBASE; HUMAN; INCIDENCE; INFORMATION RETRIEVAL; LIVER DYSFUNCTION; LIVER FUNCTION TEST; LUNG ARTERY PRESSURE; MEDLINE; META ANALYSIS; PULMONARY HYPERTENSION; RANDOMIZED CONTROLLED TRIAL (TOPIC); UNSPECIFIED SIDE EFFECT;

BOSENTAN; EFFICACY; HYPERTENSION, PULMONARY; SAFETY;

ANTIHYPERTENSIVE AGENTS; ARTERIAL PRESSURE; HUMANS; HYPERTENSION, PULMONARY; LIVER; LIVER FUNCTION TESTS; ODDS RATIO; PULMONARY ARTERY; RISK FACTORS; SULFONAMIDES; TIME FACTORS; TREATMENT OUTCOME;

EID: 84891448905     PISSN: 12263303     EISSN: 20056648     Source Type: Journal    
DOI: 10.3904/kjim.2013.28.6.701     Document Type: Article

References (24)

1. Rubin LJ. Primary pulmonary hypertension. N Engl J Med 1997;336:111-117.
2. Galie N, Manes A, Branzi A. The endothelin system in pulmonary arterial hypertension. Cardiovasc Res 2004;61:227-237.
3. Davie N, Haleen SJ, Upton PD, et al. ET(A) and ET(B) receptors modulate the proliferation of human pulmonary artery smooth muscle cells. Am J Respir Crit Care Med 2002;165:398-405.
4. Channick RN, Simonneau G, Sitbon O, et al. Effects of the dual endothelin-receptor antagonist bosentan in patients with pulmonary hypertension: a randomised placebo-controlled study. Lancet 2001;358:1119-1123.
5. Valerio G, Bracciale P, Grazia D'Agostino A. Effect of bosentan upon pulmonary hypertension in chronic obstructive pulmonary disease. Ther Adv Respir Dis 2009;3:15-21.
6. Jais X, D'Armini AM, Jansa P, et al. Bosentan for treatment of inoperable chronic thromboembolic pulmonary hypertension: BENEFiT (Bosentan Effects in iNopErable Forms of chronic Thromboembolic pulmonary hypertension), a randomized, placebo-controlled trial. J Am Coll Cardiol 2008;52:2127-2134.
7. Galie N, Rubin Lj, Hoeper M, et al. Treatment of patients with mildly symptomatic pulmonary arterial hypertension with bosentan (EARLY study): a double-blind, randomised controlled trial. Lancet 2008;371:2093-2100.
8. Rubin LJ, Badesch DB, Barst RJ, et al. Bosentan therapy for pulmonary arterial hypertension. N Engl J Med 2002;346:896-903.
9. Humbert M, Barst RJ, Robbins IM, et al. Combination of bosentan with epoprostenol in pulmonary arterial hypertension: BREATHE-2. Eur Respir J 2004;24:353-359.
10. Galie N, Beghetti M, Gatzoulis MA, et al. Bosentan therapy in patients with Eisenmenger syndrome: a multicenter, double-blind, randomized, placebo-controlled study. Circulation 2006;114:48-54.
11. Egger M, Smith GD, Phillips AN. Meta-analysis: principles and procedures. BMJ 1997;315:1533-1537.
12. Lee YH, Rho YH, Choi SJ, Ji JD, Song GG. Association of TNF-alpha-308 G/A polymorphism with responsiveness to TNF-alpha-blockers in rheumatoid arthritis: a meta-analysis. Rheumatol Int 2006;27:157-161.
13. Nath SK, Harley JB, Lee YH. Polymorphisms of complement receptor 1 and interleukin-10 genes and systemic lupus erythematosus: a meta-analysis. Hum Genet 2005;118:225-234.
14. Lee YH, Song GG. Efficacy and safety of monthly 150 mg oral ibandronate in women with postmenopausal osteoporosis: a systematic review and meta-analysis of randomized controlled trials. Korean J Intern Med 2011;26:340-347.
15. He B, Zhang F, Li X, et al. Meta-analysis of randomized controlled trials on treatment of pulmonary arterial hypertension. Circ J 2010;74:1458-1464.
16. Jadad AR, Moore RA, Carroll D, et al. Assessing the quality of reports of randomized clinical trials: is blinding necessary? Control Clin Trials 1996;17:1-12.
17. Egger M, Davey Smith G, Schneider M, Minder C. Bias in meta-analysis detected by a simple, graphical test. BMJ 1997;315:629-634.
18. Davey Smith G, Egger M. Meta-analyses of randomised controlled trials. Lancet 1997;350:1182.
19. Higgins JP, Thompson SG. Quantifying heterogeneity in a meta-analysis. Stat Med 2002;21:1539-1558.
20. Barst RJ, Langleben D, Badesch D, et al. Treatment of pulmonary arterial hypertension with the selective endothelin-A receptor antagonist sitaxsentan. J Am Coll Cardiol 2006;47:2049-2056.
21. Galie N, Hinderliter AL, Torbicki A, et al. Effects of the oral endothelin-receptor antagonist bosentan on echocardiographic and doppler measures in patients with pulmonary arterial hypertension. J Am Coll Cardiol 2003;41:1380-1386.
22. Stolz D, Rasch H, Linka A, et al. A randomised, controlled trial of bosentan in severe COPD. Eur Respir J 2008;32:619-628.
23. Provencher S, Sitbon O, Simonneau G. Treatment of pulmonary arterial hypertension with bosentan: from pathophysiology to clinical evidence. Expert Opin Pharmacother 2005;6:1337-1348.
24. Sitbon O, Humbert M, Jais X, et al. Long-term response to calcium channel blockers in idiopathic pulmonary arterial hypertension. Circulation 2005;111:3105-3111.